Athira Pharma Inc. has announced a 10-for-1 reverse stock split of its common stock, effective September 17, 2025. This move aims to increase the per-share price to meet Nasdaq's $1.00 minimum bid price requirement and improve stock marketability and liquidity. Trading on a split-adjusted basis will begin on September 18, 2025, under the ticker "ATHA." The authorized shares of common stock will be reduced from 900 million to 90 million, with the par value remaining at $0.0001.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Athira Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527198-en) on September 11, 2025, and is solely responsible for the information contained therein.
Comments